Trinity Biotech Reports $11.5–12.5M Q4 Revenue, CGM+ MARD Improvement
Trinity Biotech expects Q4 2025 revenue of $11.5–$12.5M, down from $15.9M, driven by HIV test market disruptions and transition to outsourced manufacturing, with regulatory approval for Uni-Gold HIV offshoring secured. Its next-generation CGM+ platform achieved a material MARD reduction in trials and is set to enter pivotal studies in 2026.
1. Q4 2025 Trading Performance
The company forecasts Q4 2025 revenue of $11.5M–$12.5M versus $15.9M in Q4 2024, reflecting reduced TrinScreen HIV sales due to global aid funding shifts and manufacturing transition. February 2026 approval to offshore Uni-Gold HIV production aims to convert fixed costs to variable expenses and smooth profitability.
2. CGM+ Technical Advancements and Next Steps
Clinical data covering over 650 days of testing show the updated CGM+ electronics architecture delivered a material reduction in Mean Absolute Relative Difference, meeting modern CGM accuracy standards. The modular, needle-free device leverages multimodal AI analytics, and the company plans to initiate pivotal clinical trials in 2026 ahead of global regulatory submissions.